BrYet Files IND Application for ML-016, Lead Oncology Therapeutic for Advanced Solid Tumors with Lung and/or Liver Metastases

HOUSTON, TX, March 04, 2026 (EZ Newswire) — BrYet US, Inc. (“BrYet”) — a biotechnology innovator focused on developing curative therapies for advanced cancers — announced today that it has filed an Investigational New Drug (IND) application with the U.S.…